Recent researches in metal supramolecular complexes as anticancer agents

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 5, 2010, Pages 371-395

  Zhou, Cheng He ^a   Zhang, Yi Yi ^a   Yan, Cong Yan ^a   Wan, Kun ^a   Gan, Lin Ling ^a   Shi, Yuan ^a  

^a SOUTHWEST UNIVERSITY   (China)

Author keywords

Anticancer; Cobalt; Copper; Cytotoxicity; Metal complex; Palladium; Platinum; Supramolecular drug

Indexed keywords

ANTINEOPLASTIC AGENT; BBR 3005; BBR 3571; CARBOPLATIN; CHROMIUM DERIVATIVE; CISPLATIN; COBALT COMPLEX; COPPER COMPLEX; CT 033; CT 233; DOXORUBICIN; GADOLINIUM; GALLIUM; GOLD COMPLEX; IRON COMPLEX; KP 1089; KP 46; MANGANESE DERIVATIVE; METAL COMPLEX; NICKEL COMPLEX; ORGANOTIN COMPOUND; OSMIUM DERIVATIVE; OXALIPLATIN; PLATINUM COMPLEX; RHENIUM COMPLEX; RHODIUM COMPLEX; RUTHENIUM COMPLEX; SILVER DERIVATIVE; TITANIUM DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANADIUM DERIVATIVE; ZINC COMPLEX;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COMPLEX FORMATION; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; HUMAN; IC 50; STRUCTURE ACTIVITY RELATION;

EID: 77953818341     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009050371     Document Type: Article

References (178)

1. Foye, W.O. Cancer Chemotherapeutic Agents.; American Chemical Society, Washington, DC, 1995.
2. Hellmann, K.; Carter, S.K. Fundamentals of Cancer Chemotherapy, McGraw-Hill, New York, 1987.
3. Lefranc, F.; Facchini, V.; Kiss, R. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist, 2007, 12, 1395-1403.
4. Uzzo, R.G.; Haas, N.B.; Crispen, P.L.; Kolenko, V.M. Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer. Cancer, 2008, 112, 1660-1671.
5. Zhou, C.H.; Gan, L.L.; Zhang Y.Y.; Zhang, F.F.; Wang G.Z.; Jin, L.; Geng, R.X. Review on supermolecules as chemical drugs. Sci. Chin. Ser. B-Chem., 2009, 52, 415-458.
6. Zhou, C.H.; Zhang, F.F.; Gan, L.L.; Zhang Y.Y.; Geng, R. X. Research in supramolecular chemical drugs. Sci. Chin. Ser. BChem., 2009, 39, 208-252 (in Chinese).
7. Mendoza-Ferri, M.G.; Hartinger, C.G.; Mendoza, M.A.; Groessl, M.; Egger, A.E.; Eichinger, R.E.; Mangrum, J.B.; Farrell, N.P.; Maruszak, M.; Bednarski, P.J.; Klein, F.; Jakupec, M.A.; Nazarov, A.A.; Severin, K.; Keppler, B.K. Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. J. Med. Chem., 2009, 52, 916-925.
8. Klein, A.V.; Hambley, T.W. Platinum drug distribution in cancer cells and tumors. Chem. Rev., 2009, 109, 4911-4920.
9. Baskerville-Abraham, I.M.; Boysen, G.; Troutman, J.M.; Mutlu, E.; Collins, L.; de Krafft, K.E.; Lin, W.; King, C.; Chaney, S.G.; Swenberg, J.A. Development of an ultraperformance liquid chromatography/mass spectrometry method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts. Chem. Res. Toxicol., 2009, 22, 905-912.
10. Ho, Y.P.; Au-Yeung, S.C.F.; To, K.K.W. Platinum-based anticancer Agents: Innovative design strategies and biological perspectives. Med. Res. Rev., 2003, 23, 633-655.
11. Pasqua, A.J.D.; Centerwall, C.R.; Kerwood, D. J.; Dabrowiak, J.C. Formation of carbonato and hydroxo complexes in the reaction of platinum anticancer drugs with carbonate. Inorg. Chem., 2009, 48, 1192-1197.
12. Arnesano, F.; Natile. G. Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA. Coord. Chem. Rev., 2009, 253, 2070-2081.
13. Łakomska, I. Molecular structure and antitumor activity of platinum(II) complexes containing purine analogs. Inorg. Chim. Acta, 2009, 362, 669-681.
14. Möker, J.; Thiem, J. Synthesis of novel gluco- and galactofunctionalized platinum complexes. Eur. J. Org. Chem., 2009, 28, 4842-4847.
15. Alama, A.; Tasso, B.; Novelli, F.; Sparatore, F. Organometallic compounds in oncology: implications of novel organotins as antitumor agents. Drug Discov. Today, 2009, 14, 500-508.
16. Hostetter, A.A.; Chapman, E.G.; De Rose, V.J. Rapid cross-linking of an RNA internal loop by the anticancer drug cisplatin. J. Am. Chem. Soc., 2009, 131, 9250-9257.
17. Schobert, R.; Biersack, B.; Dietrich, A.; Knauer, S.; Zoldakova, M.; Fruehauf, A.; Mueller, T. Pt(II) complexes of a combretastatin A-4 analogous chalcone: Effects of conjugation on cytotoxicity, tumor specificity, and long-term tumor growth suppression J. Med. Chem., 2009, 52, 241-246.
18. Jian, G.; Liu, Y.G.; Zingaro, R.A. Cytotoxic activities, cellular uptake, gene regulation, and optical imaging of novel platinum(II) complexes. Chem. Res. Toxicol., 2009, 22, 1705-1712.
19. Tian, T.; Mutikainen, I.; Wezel, G.P.; Aliaga-Alcalde, N.; Reedijk, J. Chemical, structural and biological studies of cis-[Pt(3-Acpy)2Cl2]. J. Inorg. Biochem., 2009, 103, 1221-1227.
20. Eryazici, I.; Moorefield, C.N.; Newkome, G.R. Square-planar Pd(II), Pt(II), and Au(III) terpyridine complexes: their syntheses, physical properties, supramolecular constructs, and biomedical activities. Chem. Rev., 2008, 108, 1834-1895.
21. Ronconi, L.; Fregona, D. The Midas touch in cancer chemotherapy: from platinum- to gold-dithiocarbamato complexes. Dalton Trans., 2009, 10670-10680.
22. Arnesano, F.; Boccarelli, A.; Cornacchia, D.; Nushi, F.; Sasanelli, R. Coluccia, M.; Natile, G. Mechanistic insight into the inhibition of matrix metalloproteinases by platinum substrates. J. Med. Chem., 2009, 52, 7847-7855.
23. Butsch, K.; Elmas, S.; Gupta, N.S.; Gust, R.; Heinrich, F.; Klein, A.; Mering, Y.; Neugebauer, M.; Ott, I.; Schafer, M.; Scherer, H.; Schurr, T. Organoplatinum(II) and -palladium(II) complexes of nucleobases and their derivatives. Organomet., 2009, 28, 3906-3915.
24. Obata, M.; Hirohara, S.; Tanaka, R.; Kinoshita, I.; Ohkubo, K.; Fukuzumi, S.; Tanihara, M.; Yano, S. In vitro heavy-atom effect of palladium(II) and platinum(II) complexes of pyrrolidine-fused chlorin in photodynamic therapy. J. Med. Chem., 2009, 52, 2747-2753.
25. Marqués-Gallego, P.; Contaldi, S.; Dulk, H.; Monari, M.; Brouwer, J.; Jaehde, U.; Kalayda, G.V.; Reedijk, J. Relevance of the leaving group for antitumor activity of new platinum(II) compounds containing anthracene derivatives as a carrier ligand. J. Inorg. Biochem., 2009, 103, 1602-1608.
26. Aris, S.M.; Nicholas P. Farrell. Towards antitumor active transplatinum compounds. Eur. J. Inorg. Chem., 2009, 1293-1302.
27. Rakić, G.M.; Grgurić-šipka, S.; KaluCerović, G.N.; Gómez-Ruiz, S.; Bjelogrlić, S.K.; Radulović, S.S.; Tešić, Ž.L. Novel transdichloridoplatinum(II) complexes with 3- and 4-acetylpyridine: Synthesis, characterization, DFT calculations and cytotoxicity. Eur. J. Med. Chem., 2009, 44, 1921-1925.
28. Navarro, M.; Higuera-Padilla, A.R.; Arsenak, M.; Taylor, P. Synthesis, characterization, DNA interaction studies and anticancer activity of platinum-clotrimazole complexes. Trans. Met. Chem., 2009, 34, 869-875.
29. Krause-Heuer, A.M.; Gr€unert, R.; K€uhne, S.; Buczkowska, M.; Wheate, N.J.; Pevelen, D.D.L.; Boag, L.R.; Fisher, D.M.; Kasparkova, J.; Malina, J.;. Bednarski, P.J; Brabec, V.; Aldrich-Wright, J.R. Studies of the mechanism of action of platinum(II) complexes with potent cytotoxicity in human cancer cells. J. Med. Chem., 2009, 52, 5474-5484.
30. Jr, R.A.C.; Woster, P.M. Recent advances in the development of polyamine analogues as antitumor agents. J. Med. Chem., 2009, 52, 4551-4573.
31. Zhao, Y.J.; Bali, M.S.; Cullinane, C.; Day, A.I.; Collins, J.G. Synthesis, cytotoxicity and cucurbituril binding of triamine linked dinuclear platinum complexes. Dalton Trans., 2009, 26, 5190-5198.
32. Xu, Z.H.; Zhang, Y.M.; Xue, Z.Q.; Yang, X.L.; Wu, Z.Y.; Guo, Z.J. DNA-binding property and antitumor activity of a cyclam bridged dinuclear platinum(II) complex. Inorg. Chim. Acta, 2009, 362, 2347-2352.
33. Zhu, J.H.; Zhao, Y.M.; Zhu, Y.Y.; Wu, Z.Y.; Lin, M.X.; He, W.J.; Wang, Y.; Chen, G.J.; Dong, L.; Zhang, J.F.; Lu, Y.; Guo, Z.J. DNA cross-linking patterns induced by an antitumor-active trinuclear platinum complex and comparison with its dinuclear analogue. Chem. Eur. J., 2009, 15, 5245-5253.
34. Rubino, S.; Portanova, P.; Girasolo, A.; Calvaruso, G.; Orecchio, S.; Stocco, G.C. Synthetic, structural and biochemical studies of polynuclear platinum(II) complexes with heterocyclic ligands. Eur. J. Med. Chem., 2009, 44, 1041-1048.
35. Vetter, C.; Kaluderoví, G.N.; Paschke, R.; Gómez-Ruiz, S.; Steinborn, D. Synthesis, structures and in vitro cytotoxicity studies of platinum(IV) complexes with N,S and S,S heterocyclic ligands. Polyhedron, 2009, 28, 3699-3706.
36. Garoufis, A.; Hadjikakou, S.K.; Hadjiliadis, N. Palladium coordination compounds as anti-viral, anti-fungal, anti-microbial and anti-tumor agents. Coord. Chem. Rev., 2009, 253, 1384-1397.
37. Zmejkovski, B.B.; KaluCerović, G.N.; Gómez-Ruiz, S.; Žižak, Ž.; Steinborn, D.; Schmidt, H.; Paschke, R.; Juranić, Z.D.; Sabo, T. J. Palladium(II) complexes with R2edda-derived ligands. Part II. Synthesis, characterization and in vitro antitumoral studies of R2eddip esters and palladium(II) complexes. Eur. J. Med. Chem., 2009, 44, 3452-3458.
38. Quiroga, A.G.; Ranninger, C.N. Contribution to the SAR field of metallated and coordination complexes studies of the palladium and platinum derivatives with selected thiosemicarbazones as antitumoral drugs. Coord. Chem. Rev., 2004, 248, 119-133.
39. Gao, E.; Liu, C.; Zhu, M. C.; Lin, H. K.; Wu, Q.; Liu, L. Current development of Pd(II) complexes as potential antitumor agents. Anti-Cancer Agents Med. Chem., 2009, 9, 356-368.
40. Štarha, P.; Trávníček, Z.; Popa, I. Synthesis, characterization and in vitro cytotoxicity of the first palladium(II) oxalato complexes involving adenine-based ligands. J. Inorg. Biochem., 2009, 103, 978-988.
41. Keter, F.K.; Ojwach, S.O.; Oyetunji, O.A.; Guzei, I.A.; Darkwa, J. Bis(pyrazolyl) palladium(II), platinum(II) and gold(III) complexes: Syntheses, molecular structures and substitution reactions with Lcysteine. Inorg. Chim. Acta, 2009, 362, 2595-2602.
42. Bakalova, A.; Varbanov, H.; Buyukliev, R.; Momekov, G.; Ivanov, D. Palladium (II) complexes with 5-methyl-5-(4-pyridyl)- 2,4-imidazoldenedione: Synthesis, thermogravimetric and cytotoxic investigation. J. Therm. Anal. Calorim., 2009, 95, 241-246.
43. Kalinowska-Lis, U.; Szmigiero, L.; Studzian, K.; Ochocki, J. Cytotoxic activity and chemical reactivity of cis-platinum(II) and transpalladium(II) complexes with diethyl (pyridinylmethyl) phosphates. Eur. J. Med. Chem., 2009, 44, 660-664.
44. Gligorijevic, N.; Todorovic, T.; Radulovic, S. Synthesis and characterization of new Pt(II) and Pd(II) complexes with 2-quinolinecarboxaldehyde selenosemicarbazone: Cytotoxic activity evaluation of Cd(II), Zn(II), NI(II), Pt(II) and Pd(II) complexes with heteroaromatic selenosemicarbazones. Eur. J Med. Chem., 2009, 44, 1623-1629.
45. Tiekink, E.R.T. Gold derivatives for the treatment of cancer. Crit. Rev. Oncol., 2002, 42, 225-248.
46. Espósito, B.P.; Najjar, R. Interactions of antitumoral platinumgroup metallodrugs with albumin. Coord. Chem. Rev., 2002, 232, 137-149.
47. McKeage, M.J.; Maharaj, L.; Berners-Price, S.J. Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria. Coord. Chem. Rev., 2002, 232, 127-135.
48. Barnard, P.J.; Berners-Price, S.J. Targeting the mitochondrial cell death pathway with gold compounds. Coord. Chem. Rev., 2007, 251, 1889-1902.
49. Ott, I. On the medicinal chemistry of gold complexes as anticancer drugs. Coord. Chem. Rev., 2009, 253, 1670-1681.
50. Ott, I.; Qian, X.H.; Xu, Y.F.; Vlecken, D.H. W.; Marques, I.J.; Kubutat, D.; Will, J.; Sheldrick, W.S.; Jesse, P.; Prokop, A.; Bagowski, C.P.A Gold(I) phosphine complex containing a naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and angiogenesis inhibitor. J. Med. Chem., 2009, 52, 763-770.
51. Barreiro, E.; Casas, J.S.; Couce, M.D.; Sánchez, A.; Sánchez-Gónzalez, A.; Sordo, J.; Varela, J.M.; López, E.M.V. J. Inorg. Biochem., 2008, 102, 184-192.
52. Barreiro, E.; Casas, J.S.; Couce, M.D.; Sánchez, A.; Sánchez- González, A.; Sordo, J.; Varela, J.M.; López, E.M.V. Synthesis, structure and cytotoxicity studies of diisopropylammonium and triethylammonium salts of triphenylphosphinegold(I) sulfanylcarboxylates. J. Inorg. Biochem., 2009, 103, 1023-1032.
53. Chui, C.H.; Wong, R.S.M.; Gambari, R.; Cheng, G.Y.M.; Yuen, M.C.W.; Chan, K.W.; Tong, S.W.; Lau, F.Y.; Lai, P.B.S.; Lama, K.H.; Ho, C.L.; Kan, C.W.; Leung, K.S.Y.; Wong, W.Y. Antitumor activity of diethynylfluorene derivatives of gold(I). Bioorg. Med. Chem., 2009, 17, 7872-7877.
54. To, Y.F.; Sun, R.W.Y.; Chen, Y.X.; Chan, V.S.F.; Yu, W.Y.; Tam, P.K.H.; Che, C.M.; Steve Lin, C.L. Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo. Int. J. Cancer, 2009, 124, 1971-1979.
55. Casini, A.; Kelter, G.; Gabbiani, C.; Cinellu, M.A.; Minghetti, G.; Fregona, D.; Fiebig, H.H.; Messori, L. Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study. J. Biol. Inorg. Chem., 2009, 14, 1139-1149.
56. Segapelo, T.V.; Guzei, I.A.; Spencer, L.C.; Zyl, W.E.V.; Darkwa, J. (Pyrazolylmethyl) pyridine platinum(II) and gold(III) complexes: Synthesis, structures and evaluation as anticancer agents. Inorg. Chim. Acta, 2009, 362, 3314-3324.
57. Castiñeiras, A.; Dehnen, S.; Fuchs, A.; García-Santos, I.; Sevillano, P. Stabilization of gold(I) and gold(III) complexes by pyridil bis(3-hexamethylene -iminylthiosemicarbazone): spectroscopic, structural and computational study. Dalton Trans., 2009, 2731-2739.
58. Aldinucci, D.; Ronconi, L.; Fregona, D. Groundbreaking. gold(III) anticancer agents. Drug Discov. Today, 2009, 14, 21-22.
59. Meijbooma, R.; Bowen, R.J.; Berners-Price, S.J. Coordination complexes of silver(I) with tertiary phosphine and related ligands. Coord. Chem. Rev., 2009, 253, 325-342.
60. Hindi, K.M.; Panzner, M.J.; Tessier, C. A.; Cannon, C.L.; Youngs, W.J. The medicinal applications of imidazolium carbene-metal complexes. Chem. Rev., 2009, 109, 3859-3884.
61. Thati, B.; Noble, A.; Creaven, B.S.; Walsh, M.; McCann, M.; Devereux, M.; Kavanagh, K.; Egan, D. A. Role of cell cycle events and apoptosis in mediating the anti-cancer activity of a silver(I) complex of 4-hydroxy-3-nitro-Coumarin- bis(phenanthroline) in human malignant cancer cells. Eur. J. Pharm., 2009, 602, 203-214.
62. Zartilas, S.; Hadjikakou, S.K.; Hadjiliadis, N.; Kyros, N.K.L.; Kubicki, M.; Baril, M.; Butler, I.S.; Karkabounas, S.; Balzarini, J. Tetrameric 1:1 and monomeric 1:3 complexes of silver(I) halides with tri(p-tolyl)-phosphine: A structural and biological study. Inorg. Chim. Acta, 2009, 362, 1003-1010.
63. Mendoza-Ferri, M.G.; Hartinger, C.G.; Mendoza, M.A.; Groessl, M.; Egger, A.E.; Eichinger, R.E.; Mangrum, J.B.; Farrell, N.P.; Maruszak, M.; Bednarski, P.J.; Klein, F.; Jakupec, M.A.; Nazarov, A.A.; Severin, K.; Keppler, B.K. Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. J. Med. Chem., 2009, 52, 916-925;
64. Kandioller, W.; Hartinger, C.G.; Nazarov, A.A.; Kuznetsov, M.L.; John, R.O.; Bartel, C.; Jakupec, M.A.; Arion, V.B.; Keppler, B.K. From pyrone to thiopyrone ligands-rendering maltol-derived ruthenium(II)-arene complexes that are anticancer active in vitro. Organometallic, 2009, 28, 4249-4251.
65. Bugarcic, T.; Habtemariam, A.; Deeth, R.J.; Fabbiani, F.P.A.; Parsons, S.;. Sadler, P.J. Ruthenium(II) arene anticancer complexes with redox-active diamine ligands. Inorg. Chem., 2009, 48, 9444-9457
66. Ott, I.; Gust, R. Non platinum metal complexes as anti-cancer drugs. Arch. Pharm. Chem. Life Sci., 2007, 340, 117-126.
67. Clarke, M.J.; Zhu, F.C.; Frasca, D.R. Non-platinum chemotherapeutic metallo pharmaceuticals. Chem. Rev., 1999, 99, 2511-2533.
68. Levina, A.; Mitra, A.; Lay, P.A. Recent developments in ruthenium anticancer drugs. Metallomics, 2009, 1, 458-470.
69. Renfrew, A. Ruthenium(II) arene compounds as versatile anticancer agents. Chimica, 2009, 63, 217-219.
70. Kandioller, W.; Hartinger, C.G.; Nazarov, A.A.; Kasser, J.; John, R.; Jakupec, M.A.; Arion, V.B.; Dyson, P.J.; Keppler, B.K. Tuning the anticancer activity of maltol-derived ruthenium complexes by derivatization of the 3-hydroxy-4-pyrone moiety. J. Org. Chem., 2009, 694, 922-929.
71. Olga, N.; Alexey, A.N.; Christian, G.H.; Bernhard, K.K.; Viktor B. DNA interactions of dinuclear RuII arene antitumor complexes in cell-free media. Biochem. Pharmacol., 2009, 77, 364-374.
72. Linares, F.; Galindo, M.A.; Galli, S.; Romero, M.A.; Navarro, J.A.R.; Barea, E. Tetranuclear coordination assemblies based on half-sandwich ruthenium(II) complexes: noncovalent binding to DNA and cytotoxicity. Inorg. Chem., 2009, 48, 7413-7420.
73. Giovagnini, L.; Mancinetti, E.; Ronconi, L.; Sitran, S.; Marchiò, L.; Castagliuolo, I.; Brun, P.; Trevisan, A.; Fregona, D. Preliminary chemico-biological studies on Ru(III) compounds with S-methyl pyrrolidine/dimethyl dithiocarbamate. J. Inorg. Biochem., 2009, 103, 774-782.
74. Wang, Y.H.; Cheng, C.C.; Lee, W.J.; Chiou, M.L.; Pai, C.W.; Wen, C.C.; Chen, W.L.; Chena, Y.H. A novel phenotype-based approach for systematically screening antiproliferation metallodrugs, Chem. Biol. Interact., 2009, 182, 84-91.
75. Walker, J.M.; McEwan, A.; Pycko, R.; Tassotto, M.L.; Gottardo, C.; Thng, J.; Wang, R.; Spivak, G.J. [Tris(pyrazolyl)methane] ruthenium complexes capable of inhibiting cancer cell growth. Eur. J. Inorg. Chem., 2009, 31, 4629-4633.
76. Reddy, V.D.; Dayal, D.; Cosenza, S.C.; Reddy, M.V.R.; Jr., W.C.P.; Adams, R. Glycal-ruthenium carbonyl clusters: Syntheses, characterization, and anticancer activity. J. Organomet. Chem., 2009, 694, 959-967.
77. J.A.; Marquúes-Gallego, P.; Reedijk, J.; Lutz, M.; Spek, A.L.; Bouwman, E. A novel ruthenium(III) complex with a tridentate dianionic P,O,O-ligand showing high cytotoxic activity. Dalton Trans., 2009, 10727-10730.
78. Katsaros, N.; Anagnostopoulou, A. Rhodium and its compounds as potential agents in cancer treatment. Crit. Rev. Oncol., 2002, 42, 297-308.
79. Bieda, R.; Ott, I.; Dobroschke, M.; Gust, A.P.R.; Sheldrick, W.S. Structure-activity relationships and DNA binding properties of apoptosis inducing cytotoxic rhodium(III) polypyridyl complexes containing the cyclic thioether [9]aneS3. J. Inorg. Biochem., 2009, 103, 698-708.
80. Bieda, R.; Ott, I.; Gust, R.; Sheldrick, W.S. Cytotoxic rhodium(III) polypyridyl complexes containing the tris(pyrazolyl)methane coligand: Synthesis, DNA binding properties and structure-activity relationships. Eur. J. Inorg. Chem., 2009, 25, 3821-3831.
81. Chifotides, H.T.; Dunbar K.R. Interactions of metal-metal-bonded antitumor active complexes with DNA fragments and DNA. Acc. Chem. Res., 2005, 38, 146-156.
82. Aguirre, J.D.; Angeles-Boza, A.M.; Chouai, A.; Turro, C.; Pellois, J.P.; Dunbar, K.R. Anticancer activity of heteroleptic diimine complexes of dirhodium: a study of intercalating properties, hydrophobicity and in cellulo activity. Dalton Trans., 2009, 48, 10806-10812.
83. Peacock, A.F.A.; Sadler, P.J. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. Chem. Asian J., 2008, 3, 1890-1899.
84. Kostrhunova, H.; Florian, J.; Novakova, O.; Peacock, A.F.A.; Sadler, P.J.; Brabec, V. DNA interactions of monofunctional organometallic osmium(II) antitumor complexes in cell-free media. J. Med. Chem., 2008, 51, 3635-3643.
85. Rijt, S.H.; Sadler, P.J. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. Drug Discov. Today, 2009, 14, 1089-1097.
86. Rijt, S.H.; Hebden, A.J.; Amaresekera, T.; Deeth, R.J.; Clarkson, G.J.; Parsons, S.; McGowan, P.C.; Sadler, P.J. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes. J. Med. Chem., 2009, 52, 7753-7764.
87. Rijt, S.H.; Peacock, A.F.A.; Johnstone, R.D.L.; Parsons, S.; Sadler, P.J. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives. Inorg. Chem., 2009, 48, 1753-1762.
88. Kong, K.V.; Leong, W.K.; Lim, L.H.K. Induction of apoptosis by hexaosmium carbonyl clusters. J. Organomet. Chem., 2009, 694, 834-839.
89. Tshuva, E.Y.; Ashenhurst, J.A. Cytotoxic titanium(IV) complexes: Renaissance. Eur. J. Inorg. Chem., 2009, 15, 2203-2218.
90. Kostova, I. Titanium and vanadium complexes as anticancer agents. Anti-Cancer Agents Med. Chem., 2009, 9, 827-842.
91. Tshuva, E.Y.; Peri, D. Modern cytotoxic titanium(IV) complexes: Insights on the enigmatic involvement of hydrolysis. Coord. Chem. Rev., 2009, 253, 2098-2115.
92. Pavlaki, M.; Debeli, K.; Triantaphyllidou, I.E.; Klouras, N.; Giannopoulou, E.; Aletras, A.J. A proposed mechanism for the inhibitory effect of the anticancer agent titanocene dichloride on tumour gelatinases and other proteolytic enzymes. J. Biol. Inorg. Chem., 2009, 14, 947-957.
93. Vessières, A.; Plamont, M.A.; Cabestaing, C.; Claffey, J.; Dieckmann, S.; Hogan, M.; Müller-Bunz, H.; Strohfeldt, K.; Tacke, M. Proliferative and anti-proliferative effects of titanium- and ironbased metallocene anti-cancer drugs. J. Organomet. Chem., 2009, 694, 874-879.
94. Immel, T.A.; Debiak, M.; Groth, U.; Brkle, A.; Huhn, T. Highly selective apoptotic cell death induced by Halo-Salane Titanium complexes. Chem. Med. Chem., 2009, 4, 738-741.
95. Gleeson, B.; Claffey, J.; Hogan, M.; Müller-Bunz, H.; Wallis, D.; Tacke, M. Novel benzyl-substituted vanadocene anticancer drugs. J. Organomet. Chem., 2009, 694, 1369-1374.
96. Gleeson, B.; Claffey, J.; Deally, A.; Hogan, M.; Méndez, L.M.M.; Müller-Bunz, H.; Patil, S.; Wallis, D.; Tacke, M. Synthesis and cytotoxicity studies of fluorinated derivatives of vanadocene Y. Eur. J. Inorg. Chem., 2009, 19, 2804-2810.
97. Benítez, J.; Guggeri, L.; Tomaz, I.; Pessoa, C.; Moreno, V.; Lorenzo, J.; Avilés, F.X.; Garat, B.; Gambino, D. A novel vanadyl complex with a polypyridyl DNA intercalator as ligand: A potential anti-protozoa and anti-tumor agent. J. Inorg. Biochem., 2009, 103, 1386-1394.
98. Singh, V.P.; Singh, S.; Narang, K.K.; Bhattacharya, D. Aluminium(III), chromium(III) and iron(III) complexes with 5-iodouracil and 5-iodouracil- histidine and their antitumour activity. J. Enzym. Inhib. Med. Chem., 2009, 24, 105-111.
99. Haas, K.L.; Franz, K.J. Application of metal coordination chemistry to explore and manipulate cell biology. Chem. Rev., 2009, 109, 4921-4960.
100. Ansari, K.I.; Grant, J.D.; Kasiri, S.; Woldemariam, G.; Shrestha, B.; Mandal, S.S. Manganese(III)-salens induce tumor selective apoptosis in human cells. J. Inorg. Biochem., 2009, 103, 818-826.
101. Ansari, K.I.; Grant, J.D.; Kasiri, S.; Mandal, S.S. Apoptosis and anti-tumour activities of manganese(III)-salen and -salphen complexes. Dalton Trans., 2009, 40, 8525-8531.
102. Zhang, Z.; He, R.; Yan, K.; Guo, Q.N.; Lu, Y.G.; Wang, X.X.; Lei, H.; Li, Z.Y. Synthesis and in vitro and in vivo evaluation of manganese(III) porphyrin-dextran as a novel MRI contrast agent. Bioorg. Med. Chem. Lett., 2009, 19, 6675-6678.
103. Chen, X.; Tang, L.J.; Sun, Y.N.; Qiu, P.H.; Liang, G. Syntheses, characterization and antitumor activities of transition metal complexes with isoflavone. J. Inorg. Biochem., 2010, 104, 379-384.
104. Schwietert, C.W.; McCue, J.P. Coordination compounds in medicinal chemistry. Coord. Chem. Rev., 1999, 184, 67-89.
105. Pahl, P.M.B.; Horwitz, L.D. Cell permeable iron chelators as potential cancer chemotherapeutic agents. Cancer Invest., 2005, 23, 683-691,.
106. Buss, J.L.; Greene, B.T.; Turner, J.; Torti, F.M.; Torti, S.V. Iron chelators in cancer chemotherapy. Curr. Top. Med. Chem., 2004, 4, 1623-1635.
107. Richardson, D.R.; Kalinowski, D.S.; Richardson, V.; Sharpe, P.C.; Lovejoy, D.B.; Islam, M.; Bernhardt, P.V. 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: Redox activity, iron complexation and characterization of their antitumor activity. J. Med. Chem., 2009, 52, 1459-1470.
108. Wen, Y.D.; Ho, Y.L.; Shiau, R.J.; Yeh, J.K.; Wu, J.Y.; Wang, W.L.; Chiou, S.J. Synergistic antitumor effect of curcumin and di nitrosyl iron complexes for against melanoma cells. J. Organomet. Chem., 2010, 695, 352-359.
109. Hille, A.; Gust, R. Relationship between anticancer activity and stereochemistry of saldach ligands and their iron(III) complexes. Arch. Pharm. Chem. Life Sci., 2009, 342, 625-631.
110. Herchel, R.; SindeÍǎr, Z.; Tŕavńičcek, Z.; Zbočril, R.; Vaňco, J. Novel 1D chain Fe(III)-salen-like complexes involving anionic heterocyclic N-donor ligands. Synthesis, X-ray structure, magnetic, 57Fe M̈ossbauer, and biological activity studies. Dalton Trans., 2009, 44, 9870-9880.
111. Galanis, A.; Karapetsas, A.; Sandaltzopoulos, R. Metal-induced carcinogenesis, oxidative stress and hypoxia signaling. Mutat. Res., 2009, 674, 31-35.
112. Ming, L.J. Structure and function of "metalloantibiotics. Med. Res. Rev., 2003, 23, 697-762.
113. Chen, Y.; Hu, L.Q. Design of anticancer prodrugs for reductive activation. Med. Res. Rev., 2009, 29, 29-64.
114. Naura, A.S.; Sharma, R. Studies on mode of action of hexaammine Co(III) chloride against diethylnitrosamine-induced hepatocarcinogenesis in mice. J. Biochem. Mol. Toxicol. 2009, 23, 193-201.
115. Erwin, R.; Vladimir, B.A.; Bernhard, K.K.; Armando, J.L.P. Electron-transfer activated metal-based anticancer drugs. Inorg. Chim. Acta, 2008, 361, 1569-1583.
116. Nagababua, P.; Latha, J.N.L.; Rajesh, M.; Satyanarayana, S. DNAbinding and cytotoxicity of the cobalt(III) ethylenediamine pyrazole complex [Co(en)2(pyz)2]3+. J. Iran. Chem. Soc., 2009, 6, 145-152.
117. Elizabeth, T.S.; Lidiane C.C.; Frederico, A.V.C.; Lorenzo, C.V.; Carlos, B.P.; Marcos D.P.; Sérgio P.M.; Marciela, S. Synthesis, characterization and biological activities of mononuclear Co(III) complexes as potential bioreductively activated prodrugs. J. Inorg. Biochem., 2009, 103, 1355-1365.
118. Hou, M.H.; Lu, W.J.; Huang, C.Y.; Fan, R.J.; Yuann, J.M.P. Effects of polyamines on the DNA-reactive properties of dimeric mithramycin complexed with cobalt(II): implications for anticancer therapy. Biochemistry, 2009, 48, 4691-4698.
119. Oluwatayo, F.I.; Elizabeth, M.H.; Wayne, O.; Robert, P.D. Pyrophosphate-bridged complexes with picomolar toxicity. J. Inorg. Biochem., 2009, 103, 1254-1264.
120. Barone, G.; Gambino, N.; Ruggirello, A.; Silvestri, A.; Terenzi, A.; Liveri, V.T. Spectroscopic study of the interaction of Ni(II)-5-triethyl ammonium methyl salicylidene ortho-phenylendiiminate with native DNA. J. Inorg. Biochem., 2009, 103, 731-737.
121. Buschini, A.; Pinelli, S.; Pellacani, C.; Giordani, F.; Ferrari, M.B.; Bisceglie, F.; Giannetto, M.; Pelosi, G.; Tarasconi, P. Synthesis, characterization and deepening in the comprehension of the biological action mechanisms of a new nickel complex with antiproliferative activity. J. Inorg. Biochem., 2009, 103, 666-677.
122. Wang, B.D.; Yang, Z.Y.; Lü, M.H.; Hai, J.; Wang, Q.; Chen, Z.N. Synthesis, characterization, cytotoxic activity and DNA binding Ni(II) complex with the 6-hydroxy chromone-3-carbaldehyde thiosemicarbazone. J. Organomet. Chem., 2009, 694, 4069-4075.
123. Atasever, B.; Ülküseven, B.; Bal-Demirci, T.; Erdem-Kuruca, S.; Solakoǧlu, Z. Cytotoxic activities of new iron(III) and nickel(II) chelates of some S-methyl-thiosemicarbazones on K562 and ECV304 cells. Invest. New Drugs, dio:10.1007/s10637-009-9272-2.
124. Bruijnincx, P.C.A.; Sadler, P.J. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol., 2008, 12, 197-206.
125. Xi, P.X.; Xu, Z.H.; Chen, F.J.; Zeng, Z.Z.; Zhang, X.W. Study on synthesis, structure, and DNA-binding of Ni, Zn complexes with 2-phenylquinoline-4-carboylhydrazide. J. Inorg. Biochem., 2009, 103, 210-218.
126. Tardito, S.; Marchiò, L. Copper compounds in anticancer strategies. Curr. Med. Chem., 2009, 16, 1325-1348.
127. Chen, D.; Milacic, V.; Frezza M.; Dou, Q.P. Metal complexes, their cellular targets and potential for cancer therapy. Curr. Pharm. Design., 2009, 15, 777-791.
128. Wadas, T.J.; Wong, E.H.; Weisman, G.R.; Anderson, C.J. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr. Pharm. Des., 2007, 13, 3-16.
129. Xie, H.Q.; Kang, Y.J. Role of copper in angiogenesis and its medicinal implications. Curr. Med. Chem., 2009, 16, 1304-1314.
130. Wang, T.; Guo, Z.J. Copper in medicine: Homeostasis, chelation therapy and antitumor drug design. Curr. Med. Chem., 2006, 13, 525-537.
131. Tan, J.; Wang, B.C.; Zhu, L.C. DNA binding and oxidative DNA damage induced by a quercetin copper(II) complex: potential mechanism of its antitumor properties. J. Biol. Inorg. Chem., 2009, 14, 727-739.
132. Chen, Z.F.; Tan, M.X.; Liu, L.M.; Liu, Y.C.; Wang, H.S.; Yang, B.; Peng, Y.; Liu, H.G.; Liang, H.; Orvigd, C. Cytotoxicity of the traditional chinese medicine (TCM) plumbagin in its copper chemistry. Dalton Trans., 2009, 10824-10833.
133. Iqbal, M.S.; Mughal, M.S.; Arif, R.; Fatima, S.; Sher, M. An in vitro study of the interaction of copper(II) salicylates with genomic DNA using gel electrophoresis and gel permeation chromatography. Chromatographia, 2009, 70, 1659-1663.
134. Ikotun, O.F. Higbee, E.M.; Ouellette, W.; Doyle, R.P. Pyrophosphate-bridged complexes with picomolar toxicity. J. Inorg. Biochem., 2009, 103, 1254-1264.
135. Teyssot, M.L.; Jarrousse, A.S.; Beaudoin, C.; Nolan, S.P.; Morel, L.; Gautier, A. Toxicity of copper(I)-NHC complexes against human tumor cells: Induction of cell cycle arrest, apoptosis, and DNA cleavage. Chem. Eur. J., 2009, 15, 314-318.
136. Prasad; A.S.; Kucuk, O. Zinc in cancer prevention. Cancer Metastasis Rev., 2002, 21, 291-295.
137. VanMolle, W.; VanRoy, M.; Bogaert, T.V.; Dejager, L.; Lint, P.V.; Vanlaere, I.; Sekikawa, K.; Kollias, G.; Libert, C. Protection of zinc against tumor necrosis factor-induced lethal inflammation dependson heat shock protein 70 and allows safe antitumor therapy. Cancer Res., 2007, 67, 7301-7307.
138. Liu, J.Y.; Lo, P.C.; Fongb, W.P.; Dennis, K.P.N. Effects of the number and position of the substituents on the in vitro photodynamic activities of glucosylated zinc(II) phthalocyanines. Org. Biomol. Chem., 2009, 7, 1583-1591.
139. Liu, J.Y.; Lo, P.C.; Jiang, X.J.; Fongb, W.P.; Dennis, K.P.N. Synthesis and in vitro photodynamic activities of di-α-substituted zinc(II) phthalocyanine derivatives. Dalton Trans., 2009, 7, 4129-4135.
140. Jiang, Q.; Zhu, J.H.; Zhang, Y.M.; Xiao, N.; Guo, Z.J. DNA binding property,nuclease activity and cytotoxicity of Zn(II) complexes of terpyridine derivatives. Biometals, 2009, 22, 297-305.
141. Wang, H.F.; Shen, R.; Tang, N. Synthesis and characterization of the Zn(II) and Cu(II) piperidinyl isoeuxanthone complexes: DNAbinding and cytotoxic activity. Eur. J. Med. Chem., 2009, 44, 4509-4515.
142. Huang, J.; Chen, Q.Y.; Wang, L.; Yun, F.H.; Jian, L.B. Synthesis, interaction with DNA and antitumor activities of zinc(II) complexes with substituted di(picolyl)amines. Chin. J. Inorg. Chem., 2009, 25, 1077-1083.
143. Tan, J.; Wang, B.C.; Zhu, L.C.; DNA binding, cytotoxicity, apoptotic inducing activity, and molecular modeling study of quercetin zinc(II) complex. Bioorg. Med. Chem., 2009, 17, 614-620.
144. Shi, L.; Mao, W.J.; Yang, Y.; Zhu, H.L. Synthesis, characterization, and biological activity of a Schiff-base Zn(II) complex. J. Coord. Chem., 2009, 62, 3471-3477.
145. Ren, Y.F.; Sun, Y.H.; Cheng, K.M.; Liu, G.F.; Shen, Y.M. Synthesis and radiolabelling of Re(CO)3-belemene derivatives as potential therapeutic radiopharmaceuticals. J. Label Compd. Radiopharm., 2009, 52, 139-145.
146. Louie, M.W.; Liu, H.W.; Lam, M.H.C.; Lau, T.C.; Lo, K.K.W. Novel luminescent tricarbonylrhenium(I) polypyridine tyraminederived dipicolylamine complexes as sensors for zinc(II) and cadmium(II) Ions. Organometallics., 2009, 28, 4297-4307.
147. Jakupec, M.A.; Untried, P.; Keppler, B.K. Pharmacological properties of cerium compounds. Rev. Physiol. Biochem. Pharmacol., 2005, 153, 101-111.
148. Fricker, S.P. The therapeutic application of lanthanides. Chem. Soc. Rev., 2006, 35, 524-533.
149. Biba, F.; Groessl, M.; Egger, A.; Roller, A.; Hartinger, C.G.; Keppler, B.K. New insights into the chemistry of the antineoplastic lanthanum complex tris(1,10-phenanthroline)- tris(thiocyanato-kN)lanthanum(III) (KP772) and its interaction with biomolecules. Eur. J. Inorg. Chem., 2009, 28, 4282-4287.
150. Biba, F.; Groessl, M.; Egger, A.; Jakupeca, M.A.; Keppler, B.K. A novel cytotoxic cerium complex: aquatrichloridobis(1,10-phenanthroline)cerium(III) (KP776). Synthesis, characterization, behavior in H2O, binding towards biomolecules, and antiproliferative activity. Chem. Biodiver., 2009, 6, 2153-2165.
151. Arambula, J.F.; Sessler, J.L.; Fountain, M.E.; Wei, W.H.; Magda, D.; Siddik, Z.H. Gadolinium texaphyrin (Gd-Tex)-malonatoplatinum conjugates: Synthesis and comparison with carboplatin in normal and Pt-resistant cell lines. Dalton Trans., 2009, 48, 10834-10840.
152. Collery, P.; Keppler, B.; Madoulet, C.; Desoize, B. Gallium in cancer treatment. Crit. Rev. Oncol. Hematol., 2002, 42, 283-296.
153. Gielen, M.; Tiekink, E.R.T. Metallotherapeutic Drugs and Metal-Based Diagnostic Agents, Wiley & Sons: New York, 2005.
154. Jakupec, M.A.; Keppler, B.K.; in: Metal Ions in Biological Systems, Siegel, A.; Siegel H.; Eds., Dekker, New York, 2004; Vol. 42, pp. 425-462.
155. Bandoli, G.; Dolmella, A.; Tisato, F. Mononuclear six-coordinated Ga (III) complexes: A comprehensive survey. Coord. Chem. Rev., 2009, 253, 56-77.
156. Timerbaev, A.R. Advances in developing tris(8-quinolinolato) gallium(III) as an anticancer drug: critical appraisal and prospects. Metallomics, 2009, 1, 193-198.
157. Valiahdi, S.M.; Heffeter, P.; Jakupec, M.A.; Marculescu, R.; Berger, W.; Rappersberger, K.; Keppler, B.K. The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis
158. Mendes, I.C.; Soares, M.A.; Santos, R.G.; Pinheiro, C.; Beraldo, H. Gallium(III) complexes of 2-pyridineformamide thiosemicarbazones: Cytotoxic activity against malignant glioblastoma, Eur. J. Med. Chem., 2009, 44, 1870-1877.
159. Gómez-Ruiz, S.; Gallego, B.; Kaluderović, M.R.; Kommera, H.; Hey-Hawkins, E.; Paschke, R.; Kaluderović, G.N. Novel gallium(III) complexes containing phthaloyl derivatives of neutral aminoacids with apoptotic activity in cancer cells. J. Organomet. Chem., 2009, 694, 2191-2197.
160. Vasiliki, V.; Maria, B.C. Chemical aspects of organotin derivatives of beta-diketones, quinonoids, steroids, and some currently used drugs: A review of the literature with emphasis on the medicinal potential of organotins. Synth. React. Inorg. Met. Org. Nan. Met. Chem., 2007, 37, 507-525.
161. Hadjikakou, S.K.; Hadjiliadis, N. Antiproliferative and anti-tumor activity of organotin compounds. Coord. Chem. Rev., 2009, 253, 235-249.
162. Nath, M.; Pokharia, S.; Yadav, R. Organotin(IV) complexes of amino acids and peptides. Coord. Chem. Rev., 2001, 215, 99-149.
163. Carraher, C.E.; Deborah, S.L. Organotin Macromolecules as Anti-Cancer Drugs, Metal-and Metalloid- Containing Macromolecules. John Wiley & Sons, New York, 2004.
164. Saxena, A.K.; Huber, F. Organotin compounds and cancer chemotherapy. Coord. Chem. Rev., 1989, 95: 109-123.
165. Gielen, M. Tin-based antitumor drugs. Coord. Chem. Rev., 1996, 151, 41-51.
166. Pellerito, L., Nagy, L. Organotin(IV) complexes formed with biologically active ligands: equilibrium and structural studies, and some biological aspects. Coord. Chem. Rev., 2002, 224, 111-150.
167. Gielen, M.; Tiekink, E.R.T. In: Tin Compounds and their Therapeutic Potential in Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: The Use of Metals in Medicine. M. Gielen, E.R.T. Tiekink (Eds.), JohnWiley & Sons, Ltd., 2005.
168. Muhammad, N.; Shah, A.; Shuja, S.; Ali, S.; Qureshi, R.; Meetsma, A.; Tahir, M.N. Organotin(IV) 4-nitrophenylethanoates: Synthesis, structural characteristics and intercalative mode of interaction with DNA. J. Organomet. Chem., 2009, 694, 3431-3437.
169. Muhammad, N.; Ali, S.; Meetsma, A.; Shaheen, F. Organotin(IV) 4-methoxyphenyl- ethanoates: Synthesis, spectroscopic characterization, X-ray structures and in vitro anticancer activity against human prostate cell lines (PC-3). Inorg. Chim. Acta, 2009, 362, 2842-2848.
170. Kang, W.L.; Wu, X.Y.; Huang, J.B. Synthesis, crystal structure and biological activities of four novel tetranuclear di-organotin(IV) carboxylates. J. Organomet. Chem., 2009, 694, 2402-2408.
171. Siddiqi. Z.A.; Shahid, M; Kumar, S; Khalid, M; Noor, S. Synthesis, crystal structure and in vitro antitumor activity of carboxylate bridged dinuclear organotin(IV) complexes. J. Organomet. Chem., 2009, 694, 3768-3774.
172. Li, W.; Zhang, Z.W.; Ren, S.M.; Sibiri, Y.; Massin, D.P.; Jiang, T.; Synthesis and antitumor activity of novel dibutyltin carboxylates of aminoglucosyl derivatives. Chem. Biol. Drug. Des., 2009, 73, 682-686.
173. Sen, A.; Chaudhuri, T.K. Synthesis and evaluation of dimethyl tin 4-cyclohexyl thiosemicarbazone as a novel antitumor agent. Exp. Oncol., 2009, 31, 22-26.
174. González, A.; Gómez, E.; Cortés-lozada, A.; Hernández, S.; Ramírez-apan, T.; Nieto-camacho, A. Heptacoordinate tin(iv) compounds derived from pyridine schiff bases: synthesis, characterization, in vitro cytotoxicity, anti-inflammatory and antioxidant activity. Chem. Pharm. Bull., 2009, 57, 5-15.
175. Basu, T.S.; Basu, S.; Vos, D.; Linden, A. Amino acetate functionalized schiff base organotin(IV) complexes as anticancer drugs: synthesis, structural characterization, and in vitro cytotoxicity studies. Invest. New Drugs, 2009, 27, 419-431.
176. Alama, A.; Viale, M.; Cilli, M.; Bruzzo, C.; Novelli, F.; Tasso, B.; Sparatore, F. In vitro cytotoxic activity of tri-nbutyltin(IV)lupinylsulfide hydrogen fumarate (IST-FS 35) and preliminary antitumor activity in vivo. Invest. New Drugs, 2009, 27, 124-130.
177. Gómez-Ruiz, S.; Prashar, S.; Walther, T.; Fajardo, M.; Steinborn, D.; Reinhard, P.; Kaluderović, G.N. Cyclopentadienyltin(IV) derivatives: synthesis, characterization and study of their cytotoxic activities. Polyhedron, 2010, 29, 16-23.
178. Gajewska, M.; Luzyanin, K.V.; Li, Q.S.; Cui, J.R.; Pombeiro, A.J.L. Cyclic trinuclear diorganotin(IV) complexes - the first tin compounds bearing oximehydroxamate ligands: Synthesis, structural characterization and high in vitro cytotoxicity. Eur. J. Inorg. Chem., 2009, 25, 3765-3769.